Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.77B P/E - EPS this Y -22.90% Ern Qtrly Grth -
Income -204.62M Forward P/E -29.48 EPS next Y 55.00% 50D Avg Chg 5.00%
Sales 512.4M PEG -0.55 EPS past 5Y - 200D Avg Chg -15.00%
Dividend N/A Price/Book 6.36 EPS next 5Y 25.00% 52W High Chg -39.00%
Recommedations 2.60 Quick Ratio 4.29 Shares Outstanding 161.84M 52W Low Chg 40.00%
Insider Own 0.42% ROA -19.32% Shares Float 119.51M Beta 0.67
Inst Own 94.05% ROE -40.94% Shares Shorted/Prior 9.97M/9.67M Price 17.10
Gross Margin 32.70% Profit Margin -39.93% Avg. Volume 1,696,239 Target Price 18.88
Oper. Margin -40.33% Earnings Date Nov 7 Volume 27,278 Change 2.09%
ACADIA Pharmaceuticals Inc. News
09/13/22 Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review
09/12/22 Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
09/07/22 Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound?
09/01/22 Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
08/30/22 Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to Trade
11:00 AM Acadia (ACAD) Upgraded to Buy: What Does It Mean for the Stock?
08/09/22 Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
08/09/22 Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates
08/08/22 Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
08/08/22 Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
08/05/22 FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions
08/04/22 UPDATE 1-U.S. FDA declines to approve expanded use of Acadia's antipsychotic drug
08/04/22 Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
08/01/22 Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
07/27/22 Investors five-year losses grow to 52% as the stock sheds US$212m this past week
07/25/22 Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
07/19/22 Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate
07/18/22 Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
07/08/22 Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

ACAD Chatroom

User Image LiquidSignals Posted - 2 hours ago

SuperBearish Trade Idea (Actionable) Strategy: BUY $ACAD September 30, 2022 $16.50 PUTS Buy in Price: $0.52 - $0.57 Take Profits: 1. $0.76 2. $0.84 3. $0.92 Stop Bleeding: $0.46 Estimated Profit: 47% Exit Within: 56 Minutes View Verified Track Record on Profile @LiquidSignals

User Image ChartMill Posted - 18 hours ago

$ACAD: The Revenue is expected to grow by 18.06% on average over the next 5 years. This is quite good. https://www.chartmill.com/stock/analyzer/stock/ACAD?view=fundamental-analysis&key=e7eafe89-ad6b-46b2-bdda-a27bd457b755&utm_source=stocktwits&utm_medium=FA&utm_content=ACAD&utm_campaign=social_tracking

User Image JackRowe Posted - 1 day ago

Took loss on $ACAD September 30 17.00c (-19.2%)

User Image LiquidSignals Posted - 1 day ago

SuperBearish Trade Idea (Actionable) Strategy: BUY $ACAD September 30, 2022 $16.50 PUTS Buy in Price: $0.52 - $0.60 Take Profits: 1. $0.62 2. $0.68 3. $0.75 Stop Bleeding: $0.46 Estimated Profit: 19% Exit Within: 53 Minutes View Verified Track Record on Profile @LiquidSignals

User Image LiquidSignals Posted - 1 day ago

SuperBearish Trade Idea (Actionable) Strategy: BUY $ACAD September 30, 2022 $16.50 PUTS Buy in Price: $0.52 - $0.60 Take Profits: 1. $0.74 2. $0.81 3. $0.89 Stop Bleeding: $0.46 Estimated Profit: 42% Exit Within: 38 Minutes View Verified Track Record on Profile @LiquidSignals

User Image LiquidSignals Posted - 2 days ago

SuperBearish Trade Idea (Actionable) Strategy: BUY $ACAD September 30, 2022 $16.50 PUTS Buy in Price: $0.52 - $0.60 Take Profits: 1. $0.76 2. $0.84 3. $0.92 Stop Bleeding: $0.46 Estimated Profit: 47% Exit Within: 38 Minutes View Verified Track Record on Profile @LiquidSignals

User Image Imonster08 Posted - 3 days ago

$ACAD this is not to be interpreted as a good thing but as a mere insult to impudent bears. Choke on one https://youtu.be/WACVR_3_a6U

User Image LiquidSignals Posted - 3 days ago

SuperBearish Trade Idea (Actionable) Strategy: BUY $ACAD September 23, 2022 $16.50 PUTS Buy in Price: $0.40 - $0.50 Take Profits: 1. $0.60 2. $0.66 3. $0.73 Stop Bleeding: $0.35 Estimated Profit: 51% Exit Within: 54 Minutes View Verified Track Record on Profile @LiquidSignals

User Image SBL71 Posted - 4 days ago

$ACAD well if ya have cash I guess ya just watch the s$&@ show unfold.

User Image ChartMill Posted - 5 days ago

After market losers: $ACAD, $WGO and $QFIN https://www.chartmill.com/stock/stock-screener?v=5&f=s_aml,p_pg10,v1_50b500,exch_us&utm_source=stocktwits&utm_medium=screener&utm_content=Stock_Screener:_after_market_losers&utm_campaign=social_tracking

User Image MarketBeat Posted - 5 days ago

ACADIA Pharmaceuticals upgraded by StockNews.com to buy. https://www.marketbeat.com/r/1820645 $ACAD

User Image mcollins4 Posted - 5 days ago

$ACAD TD Ameritrade is showing ACAD down 6.32. Anybody else seeing this?

User Image georgeyann Posted - 5 days ago

$ACAD BO target: $ACAD ($50); $KPTI ($28)

User Image NoOriginality Posted - 5 days ago

$ACAD Will find support over $18 heading toward Friday.

User Image zeustony88 Posted - 5 days ago

$ACAD Hold $18. Added at $18.05

User Image STCKPRO Posted - 6 days ago

$ACAD NEW ARTICLE : Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook https://www.stck.pro/news/ACAD/34506837

User Image stockilluminati Posted - 6 days ago

$ACAD https://www.stockilluminati.com/acad/news.php - Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook

User Image STCKPRO Posted - 1 week ago

$ACAD NEW ARTICLE : Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2022 Update https://www.stck.pro/news/ACAD/34473449

User Image stockilluminati Posted - 1 week ago

$ACAD https://www.stockilluminati.com/acad/news.php - Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2022 Update

User Image shortvolumes Posted - 1 week ago

2022-09-16 Short sale volume (not short interest) for $ACAD is 65%. http://shortvolumes.com/?t=ACAD via @shortvolumes

User Image LiquidSignals Posted - 1 week ago

SuperBearish Trade Idea (Actionable) Strategy: BUY $ACAD September 23, 2022 $18.00 PUTS Buy in Price: $2.25 - $4.00 Take Profits: 1. $2.61 2. $2.87 3. $3.16 Stop Bleeding: $1.98 Estimated Profit: 16% Exit Within: 35 Minutes View Verified Track Record on Profile @LiquidSignals

User Image quantcha Posted - 1 week ago

StockTwits Trending Alert: Trading recent interest in ACADIA PHARMACEUTICALS $ACAD https://wp.me/p5bLGB-hPsL

User Image LiquidSignals Posted - 1 week ago

SuperBearish Trade Idea (Actionable) Strategy: BUY $ACAD September 23, 2022 $18.00 PUTS Buy in Price: $2.25 - $4.00 Take Profits: 1. $3.10 2. $3.42 3. $3.76 Stop Bleeding: $1.98 Estimated Profit: 38% Exit Within: 57 Minutes View Verified Track Record on Profile @LiquidSignals

User Image marketchameleonwins Posted - 1 week ago

$ACAD upcoming event September 19: Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Virtual Summit. Options expiring on September 23 that cover the event have an implied move of ±6.0% https://tinyurl.com/2ozdwsp2

User Image NoOriginality Posted - 1 week ago

$ACAD Let's see how today's $18 calls fare.

User Image LiquidSignals Posted - 1 week ago

SuperBearish Trade Idea (Actionable) Strategy: BUY $ACAD September 23, 2022 $17.50 PUTS Buy in Price: $0.85 - $2.90 Take Profits: 1. $0.97 2. $1.07 3. $1.17 Stop Bleeding: $0.75 Estimated Profit: 14% Exit Within: 42 Minutes View Verified Track Record on Profile @LiquidSignals

User Image LiquidSignals Posted - 1 week ago

SuperBearish Trade Idea (Actionable) Strategy: BUY $ACAD September 23, 2022 $17.50 PUTS Buy in Price: $0.85 - $3.90 Take Profits: 1. $1.36 2. $1.50 3. $1.65 Stop Bleeding: $0.75 Estimated Profit: 60% Exit Within: 32 Minutes View Verified Track Record on Profile @LiquidSignals

User Image LoganFive Posted - 1 week ago

$ACAD

User Image EFhutton420 Posted - 1 week ago

$ACAD the Retts drug will be approved, prob even before the PDUFA date. But soon we should start hearing Stevie start to really hype the Schizo study. Just like with DRP, we will hear how excited the FDA is and how well they are working with Acadia and all the warm and fuzzies. And again it will be all lies and they'll get a CRL, probably even with no ADCOM. They hype will start with the EC in Nov.

User Image SBL71 Posted - 1 week ago

$ACAD interesting all those posters’ predictions of single digits seem to…we’ll be totally wrong. Like way off the market. Not like zip code wrong but orders of magnitude wrong.

Analyst Ratings
Mizuho Neutral Aug 10, 22
Goldman Sachs Neutral Aug 10, 22
Morgan Stanley Equal-Weight Aug 9, 22
Mizuho Neutral Aug 9, 22
Goldman Sachs Neutral Aug 9, 22
RBC Capital Outperform Aug 9, 22
HC Wainwright & Co. Buy Aug 9, 22
SVB Leerink Outperform Aug 9, 22
Cowen & Co. Outperform Aug 8, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Option 0 1,893 3,995 06/10/22
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Sell 17.91 653 11,695 3,342 06/10/22
DAVIS STEPHEN CEO CEO Apr 29 Sell 18.18 5,483 99,681 75,875 05/03/22
Stankovic Srdjan R. President President Apr 29 Sell 18.18 2,865 52,086 55,188 05/03/22
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 29 Sell 18.18 894 16,253 16,742 05/03/22
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Sell 18.18 552 10,035 3,437 05/03/22
Kihara James Principal Accounting.. Principal Accounting Officer Apr 07 Sell 27.05 1,025 27,726 2,433 04/11/22
Kihara James Principal Accounting.. Principal Accounting Officer Feb 23 Option 0 840 840 02/25/22
Kihara James Principal Accounting.. Principal Accounting Officer Feb 23 Sell 23.8 359 8,544 481 02/25/22
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Feb 23 Sell 23.8 472 11,234 2,422 02/25/22
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Feb 23 Option 0 1,106 2,894 02/25/22
KIM AUSTIN D. EVP & General Counse.. EVP & General Counsel Feb 23 Option 0 2,213 15,413 02/25/22
KIM AUSTIN D. EVP & General Counse.. EVP & General Counsel Feb 23 Sell 23.8 782 18,612 14,631 02/25/22
Stankovic Srdjan R. President President Feb 23 Option 0 4,919 49,938 02/25/22
Stankovic Srdjan R. President President Feb 23 Sell 23.8 1,501 35,724 48,437 02/25/22
DAVIS STEPHEN CEO CEO Feb 23 Option 0 10,945 69,661 02/25/22
DAVIS STEPHEN CEO CEO Feb 23 Sell 23.8 3,928 93,486 65,733 02/25/22
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Jan 06 Sell 23.05 538 12,401 1,788 01/10/22
KIM AUSTIN D. EVP & General Counse.. EVP & General Counsel Jan 06 Sell 23.05 574 13,231 13,200 01/10/22
Stankovic Srdjan R. President President Jan 06 Sell 23.05 1,937 44,648 45,019 01/10/22
DAVIS STEPHEN CEO CEO Jan 06 Sell 23.05 3,718 85,700 58,716 01/10/22
Stankovic Srdjan R. President President Oct 15 Sell 17.41 1,338 23,295 38,065 10/19/21
DAVIS STEPHEN CEO CEO Oct 15 Sell 17.41 2,963 51,586 52,906 10/19/21
Ridloff Elena EVP and CFO EVP and CFO Apr 30 Sell 20.33 1,032 20,981 10,553 04/30/21
KIM AUSTIN D. EVP & General Counse.. EVP & General Counsel Apr 30 Sell 20.33 1,054 21,428 11,371 04/30/21
Stankovic Srdjan R. President President Apr 30 Sell 20.33 4,230 85,996 36,434 04/30/21
DAVIS STEPHEN CEO CEO Apr 30 Sell 20.33 7,850 159,590 49,312 04/30/21
Ridloff Elena EVP and CFO EVP and CFO Feb 08 Sell 50.61 2,051 103,801 8,340 02/08/21
DAVIS STEPHEN CEO CEO Feb 08 Sell 50.61 14,195 718,409 28,900 02/08/21
Stankovic Srdjan R. President President Feb 08 Sell 50.61 8,429 426,592 31,049 02/08/21
KIM AUSTIN D. EVP & General Counse.. EVP & General Counsel Feb 08 Sell 50.61 2,107 106,635 9,911 02/08/21
Stankovic Srdjan R. President President Jan 14 Sell 55.01 700 38,507 20,247 01/14/21
Stankovic Srdjan R. President President Jan 14 Option 18.12 700 12,684 20,947 01/14/21
YANG MICHAEL J. EVP and CCO EVP and CCO Jan 08 Sell 53.34 1,120 59,741 8,059 01/08/21
KIM AUSTIN D. EVP & General Counse.. EVP & General Counsel Jan 08 Sell 53.34 678 36,165 5,518 01/08/21
Ridloff Elena EVP and CFO EVP and CFO Jan 08 Sell 53.34 1,016 54,193 3,901 01/08/21
Stankovic Srdjan R. President President Jan 08 Option 27.75 91,352 2,535,018 49,980 01/08/21
Stankovic Srdjan R. President President Jan 08 Sell 54.56 93,077 5,078,281 20,247 01/08/21
DAVIS STEPHEN CEO CEO Jan 08 Sell 53.34 3,484 185,837 24,482 01/08/21
Stankovic Srdjan R. President President Nov 20 Sell 53.5 2,728 145,948 16,528 11/20/20
YANG MICHAEL J. EVP and CCO EVP and CCO Oct 19 Sell 42.56 1,247 53,072 6,457 10/19/20
Stankovic Srdjan R. President President Oct 19 Sell 42.56 1,297 55,200 13,006 10/19/20
DAVIS STEPHEN CEO CEO Oct 19 Sell 42.56 2,960 125,978 14,786 10/19/20